Insight 数据库/医药资讯/会前通知丨BIO APAC 多的是你不知道的事！

会前通知丨BIO APAC 多的是你不知道的事！

2021-01-15 00:00:00本文来源: Insight数据库

点击蓝字 关注我们

会议日期及地点

会议时间：2021年1月20日-21日

会议酒店：上海静安希尔顿逸林酒店，3层，铭悦宴会厅、铭德宴会厅

酒店地址：上海静安区西藏北路558号

支持机构

上下滑动,阅览机构信息

1.SAPA

Founded in 1993, the Sino-American Pharmaceutical Professionals Association (SAPA) grew rapidly and has become one of the most active and well-recognized Chinese-heritage enduring professional organizations in the United States. SAPA is an independent, nonprofit and professional organization with over 6,000 members in USA, China, Hong Kong, Taiwan and Japan. Its headquarters is based in the tri-state area (NY-NJ-CT) with six regional chapters in New England, Greater Philadelphia and California bay area, and one chapter in Shanghai, China.

2. BayHelix

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.

3.CBA

The Chinese Biopharmaceutical Association-USA (CBA) is one of the largest Chinese American professional associations in the US founded in 1995. CBA is an independent, non-political, and non-profit professional organization headquartered in the Washington DC area. The membership now comprises more than 3,000 biopharma-related professionals from industry, academia, and government. Over 80 percent of the members hold Ph.D., M.D. and/or J.D. degrees. CBA also has over one hundred Institutional Members. The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to promote technology transfer and business collaborations between the United States and China.

4.KoreaBIO

Korea Biotechnology Industry Organization (KoreaBIO) is an association established as result of merger between three different industry associations in the biotechnology field in November 2008.

KoreaBIO promotes communication among all bio-industry related organizations and is striving to create a sustainable biotechnology industry ecosystem.

KoreaBIO is central organization with around 500 members from major pharma & biotechnology enterprises to special members, representing the biotechnology industry of Korea. KoreaBIO also develops various training and policy-making programs to serve the member companies more efficiently and promotes co-operation, investment relations, and technological collaborations around the world.

5.BiG

2014年2月，一个非营利性专业机构：BiG生物医药创新社（Biologics Innovation Group）在充满药味的上海张江应运而生，旨在为中国生物医药行业的发展创造一个滋养原创的生态环境。BiG 持续坚持非营利机制；坚持“会员所有、会员自治、服务会员“（Of member, by member, for member）的治理原则。六载春秋，从成立之初的21人，日渐壮大已成长拥有400余位个人会员、20家企业会员的生物医药创新社群。

6.上海医药行业协会

上海医药行业协会于1986年11月12日由上海医药行业22个单位倡议发起组建，并经原中共上海市工业工作委员会和上海市经济委员会批准于1987年1月5日正式成立。

协会是以上海医药企事业单位为主体、自愿组织的社会经济团体。2012年协会首批获得“中国社会组织评估等级5A级”证书，2018年再次通过“中国社会组织评估等级5A级”复评。

协会以“服务企业、规范行业、发展产业”为宗旨，致力于技术服务、品牌服务、咨询服务、政策服务、信息服务、培训服务、价格统计服务、行业名优产品评审及考察交流等服务，积极完成政府机构改革后委托和转移的职能，努力形成自己的特色服务项目。

协会秘书处下设办公室、科技咨询部、信息部、培训部等职能部门，编辑发行学术期刊《上海医药》、内部刊物《协会动态》和电子刊物《科技资讯》、《每周信息》等。协会组建新技术新技能专业委员会、特殊感染防治专业委员会、血液病临床与医学转化专业员会、市场和品牌专业委员会、信息化专业委员会、生物技术专业委员会、价格管理专业委员会、安全管理专业委员会及上海医药杂志编委会，形成具有行业影响力的专家库、知识库和信息库，为行业发展进步提供全方位的专业支持。

协会积极发挥政府与企业之间的桥梁和纽带作用，及时反映企业要求，准确传达政府意图，源头参与相关行业政策法规的制定，不断推进协会各项工作高效合规开展。

7.雅法全球医疗

雅法全球医疗（YAFO Life Science）是雅法资本旗下的医疗大健康部门。专注于帮助中国创新药企业达成海内外市场授权、股权融资、产品交易、及提供寻找和引进海外标的服务；同时协助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。雅法全球医疗专注以下业务：

1. 卖方投行业务：帮助海内外先进医疗科技公司在中国及境外的融资、并购和产品授权(licensing)等；

2. 买方顾问服务：为中国医疗企业提供海外市场咨询服务，寻找海外投资、并购标的，及协助达成药品和器械等商业授权合作；

3. 基金投资：与战略伙伴建立私募股权基金，投资引进成熟海外医疗技术和项目。

8.RDPAC

中国外商投资企业协会药品研制和开发行业委员会（RDPAC）是一个由42家具备研究开发能力的跨国制药企业组成的非营利组织，隶属于“中国外商投资企业协会”。RDPAC于2014年在京成立一家外商独资咨询类公司即北京阿迪派克国际咨询有限公司，并正式委托和授权后者作为RDPAC官网运营单位。

目前，RDPAC会员公司已在中国设立了49家工厂，31个研发中心，在过去两年，RDPAC成员向中国市场引进100余个创新药物，占同期中国市场所有上市创新药物的80%。

RDPAC成员与中国政府、本土医药企业抱有一个共同的愿望，即希望中国成为医药创新大国。RDPAC期待有机会和中国政府共同努力、协同发展，实现这一愿望，使创新药物惠及更多中国和全球患者。

9.NDFC

The New Drug Founders Club was founded in April, 2015, to form a network for founders of companies focusing on innovative new drug R&D and of companies providing relevant services. The club is highly prestigious in that only founders of such companies and people well-recognized for having special and major contributions to new drug R&D in China (including China R&D heads of multinational companies, R&D heads of major domestic companies, partners of VC, and other nationally recognized leaders in new drug R&D) can be admitted to the club. This feature distinguish this club from any other professional organizations in China or the world.

新药创始人俱乐部（New Drug Founders Club)于2015年3月27日成立，是一个汇集新药研发创业者，以分享经验，互相帮助为主要形式，秉承“创新、务实、分享、成长”理念，推动国家新药研发事业为目的的非营利性的企业家服务机构。俱乐部专注于新药邻域的创业者，已在中国树立了品牌并具有良好的会员粘性。通过会员资源的主动聚集，逐步搭建起“智库平台”、“媒体渠道”、“融资平台”，为会员创业及公司发展提供实质性的帮助。俱乐部目前拥有个人会员330位，企业会员2家，均为新药研发公司，新药CRO、新药技术平台创始人，生物医药基金创始人或负责人，或对中国创新药事业有杰出贡献或影响力的人士，其中有70余位会员为国家级重大人才引进工程，现有上市企业20余家。

全体大会

全球视野下的医药产业合作新征程